Renaissance Technologies LLC cut its holdings in shares of Daxor Co. (NYSEAMERICAN:DXR) by 31.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,800 shares of the company’s stock after selling 17,900 shares during the period. Renaissance Technologies LLC owned about 1.04% of Daxor worth $258,000 as of its most recent SEC filing.
Shares of DXR stock opened at $7.37 on Friday. Daxor Co. has a one year low of $3.40 and a one year high of $21.66.
ILLEGAL ACTIVITY WARNING: This news story was reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://weekherald.com/2018/11/10/daxor-co-dxr-stake-decreased-by-renaissance-technologies-llc.html.
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia.
Read More: Why do companies engage in swaps?
Want to see what other hedge funds are holding DXR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Daxor Co. (NYSEAMERICAN:DXR).
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.